Skinny labelling in the Australian context: an overview
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be protected by several different patent claim formats, including method of...
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be...
Read More
Pharmaceutical patent term extension in Australia
This article was first published in the 2023 Pharmaceutical Patent Review. Patent term extensions (PTEs) can be of great commercial importance, and in recent years have become of particular interest...
This article was first published in the 2023 Pharmaceutical Patent Review. Patent term extensions (PTEs) can be of great commercial...
Read More
Infringement of second medical use claims | Federal Court decision adds guidance
In pharmaceutical patent litigation, issues concerning infringement of method of treatment and Swiss-style claims covering new indications for known substances arise frequently. In this article, we discuss the recent...
In pharmaceutical patent litigation, issues concerning infringement of method of treatment and Swiss-style claims covering new indications for known...
Read More
The 2023 Pharmaceutical Patent Review
Welcome to Spruson & Ferguson’s wrap-up of the most notable developments in pharmaceutical patent law in Australia in 2023. The past year saw a number of important Federal Court...
Welcome to Spruson & Ferguson’s wrap-up of the most notable developments in pharmaceutical patent law in Australia in 2023....
Read More
ToolGen unsuccessful in landmark CRISPR patent appeal
The Federal Court of Australia has delivered judgement in Australia’s landmark CRISPR patent dispute, finding that none of the claims in ToolGen Inc.’s patent application for platform CRISPR technologies...
The Federal Court of Australia has delivered judgement in Australia’s landmark CRISPR patent dispute, finding that none of the...
Read More
No pay day for Commonwealth in Sanofi pharmaceutical damages claim
Background In the keenly awaited judgment in Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis)  FCAFC 97, the Full Court of the Federal Court of Australia has upheld the trial judge’s decision that...
Background In the keenly awaited judgment in Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis)  FCAFC 97, the Full Court of the Federal...
Read More
The Nobel Prize Winners 2022 patent snapshot: Chemistry
The Nobel Committees have recently announced the much-anticipated Nobel Prize winners of 2022, honouring the contributions that, as per Alfred Nobel’s will of 1895, “have conferred the greatest benefit...
The Nobel Committees have recently announced the much-anticipated Nobel Prize winners of 2022, honouring the contributions that, as per...
Read More
The Nobel Prize Winners 2022 patent snapshot: Physiology or Medicine
The Nobel Committees have recently announced the much-anticipated Nobel Prize winners of 2022, honouring the contributions that, as per Alfred Nobel’s will of 1895, “have conferred the greatest benefit...
The Nobel Committees have recently announced the much-anticipated Nobel Prize winners of 2022, honouring the contributions that, as per...
Read More
Australian patent office refuses to extend the time for making biological deposits
The Budapest Treaty provides a mechanism whereby patent applicants can sufficiently “describe” a biological invention by making a deposit of biological material with a recognised international depositary authority. To...
The Budapest Treaty provides a mechanism whereby patent applicants can sufficiently “describe” a biological invention by making a deposit...
Read More